This requires Flash to play. Click here to download.
MERCK

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Patient Product Information

Proven Efficacy With a
Durable Response

Median Response Duration Was Not Reached

Majority (59%) of responses (13/22) continued at time of analysis
  • Duration of response: Measured from the time when an objective response was first documented to the time when the SWAT score increased by more than 50% of the difference between the baseline SWAT score and the best SWAT score (nadir). Confirmed by a second assessment at 1 to 4 weeks later, if possible.
  • When end of response was defined as a 50% increase in SWAT score from the nadir, the estimated median response duration was approximately 5.6 months or 168 days (range: 34–329 days).

Selected Important Safety Information

  • Gastrointestinal (GI) disturbances (eg, nausea, vomiting, and diarrhea) may require antiemetics, antidiarrheals, and fluid and electrolyte replacement to prevent dehydration. Adequately control preexisting GI disturbances before beginning therapy with ZOLINZA.
  • Based on reports of dehydration as a serious drug-related adverse event in clinical trials, instruct patients to drink at least 2 L/day of fluids for adequate hydration.

Before prescribing ZOLINZA, please read the physician Prescribing Information. The Patient Product Information is also available.

Back to Top


ZOLINZA is a registered trademark of Merck & Co., Inc. Copyright © 2008 Merck & Co., Inc. All rights reserved.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico.

20750170(10)-03/07-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck & Co., Inc.